Among 53 patients with HER2 over-expression breast cancer, including Luminal B-like (HER2 positive) and HER2 positve (non-luminal) subtypes, 38 patients had trastuzumab for both neoadjuvant and adjuvant setting. Here, ERBB2 is linked to breast carcinoma.